Form 8-K - Current report:
SEC Accession No. 0001140361-26-020402
Filing Date
2026-05-11
Accepted
2026-05-11 09:20:50
Documents
11
Period of Report
2026-05-08
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20072568_8k.htm   iXBRL 8-K 41964
  Complete submission text file 0001140361-26-020402.txt   171717

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA auph-20260508.xsd EX-101.SCH 3880
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE auph-20260508_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE auph-20260508_pre.xml EX-101.PRE 16054
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20072568_8k_htm.xml XML 4075
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 26961165
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)